Table 1 Clinical profile of all patients receiving pre-phase therapy in comparison to the historical pre-phase cohort
From: Pre-phase strategy to mitigate first cycle effect in diffuse large B cell lymphoma
Clinical variables | Historical pre-phase cohort (N = 50) | Total pre-phase cohort (N = 188) |
|---|---|---|
Mean age (years) | 51.7 | 52.9 |
 Male | 29 (58%) | 110 (58.5%) |
 Female | 21 (42%) | 78 (41.5%) |
Mean LDH (U/L) | ||
 Prior to pre-phase | 441.4 | 398 |
 Post-pre-phase | 338.6 | 301 |
Cell of origin | ||
 GCB | 21 (42%) | 85 (45.2%) |
 Non-GCB | 29 (58%) | 103 (54.8%) |
Stage (N) | ||
 I | 0 (0%) | 15 (8%) |
 II | 17 (34%) | 60 (31.9%) |
 III | 13 (26%) | 39 (20.7%) |
 IV | 20 (40%) | 74 (39.4%) |
Extra-nodal disease | 29 (58%) | 100 (53.2%) |
IPI score (score) | ||
 Low risk (0, 1) | 9 (18%) | 58 (30.9%) |
 Low intermediate (2) | 19 (38%) | 58 (30.9%) |
 High intermediate (3) | 12 (24%) | 41 (21.8%) |
 High risk (4, 5) | 10 (20%) | 31 (16.5%) |
Treatment | ||
 Rituximab based | 16 (32%) | 106 (56.4%) |
 Non Rituximab based | 34 (68%) | 82 (43.6%) |
Prophylactic growth factor (G-CSF) | 12 (24%) | 76 (40.4%) |